Evidence map›Paper›PMID 34529688›Full record

ArticlePloS one2021

Lower p66Shc promoter methylation in subjects with chronic renal failure.

Radhia Hamdi, Amana Saadallah-Kallel, Slima Ferchichi-Trimeche, Raja Mokdad-Gargouri, Abdelhedi Miled, Bachir Benarba

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Radhia HamdiFaculty of Pharmacy, Research unit of clinical and molecular biology (UR17ES29), Department of biochemistry, University of Monastir, Monastir, Tunisia.ORCID 0000-0003-3637-3311
Amana Saadallah-KallelLaboratory of Molecular Biotechnology of Eukaryotes, Biotechnology Center, University of Sfax, Sfax, Tunisia.
Slima Ferchichi-TrimecheFaculty of Pharmacy, Research unit of clinical and molecular biology (UR17ES29), Department of biochemistry, University of Monastir, Monastir, Tunisia.
Raja Mokdad-GargouriLaboratory of Molecular Biotechnology of Eukaryotes, Biotechnology Center, University of Sfax, Sfax, Tunisia.
Abdelhedi MiledCHU Research Unit, Farhat Hached, Sousse, Tunisia.
Bachir BenarbaFaculty of Nature and Life, Laboratory Research on Biological Systems and Geomatics, University of Mascara, Mascara, Algeria.
University of Monastir · TNUniversity of Sfax · TNHôpital Farhat Hached · TNUniversité Mustapha Stambouli de Mascara · DZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the correlation between DNA methylation of p66Shc promoter and some markers of inflammatory and oxidative stress in chronic renal failure (CRF) patients compared with healthy subjects.

methodsAn observational cross-sectional study was conducted in the nephrology department at Sidi Bouzid Regional Hospital (Tunisia). In total, 39 patients with CRF and 37 healthy subjects were included. Several biochemical parameters were measured. Furthermore, markers of the oxidative and inflammatory status (MDA, TAS, SOD, and CRP) were evaluated. The p66Shc methylation status was determined using the methylation-specific PCR.

resultsOur results showed that levels of blood glucose, urea, creatinine, uric acid, ChT, TG, albuminuria, CRP and MDA were significantly elevated in CRF patients compared to controls. Furthermore, p66Shc promoter region was highly demethylated in CRF patients compared to healthy controls (84% vs 4%). Our data showed a positive correlation between p66Shc hypomethylation and levels of MDA (r = 0.93; p<0, 05) and CRP (r = 0.89; P <0, 05), as well as a significant negative correlation between p66Shc hypomethylation, TAS (r = -0.76; P <0, 05) and SOD (r = -0.77; p<0, 05) levels. Similarly, there was a positive correlation between p66Shc hypomethylation and the disease stages. Importantly, multiple regression analysis showed that p66shc DNA hypomethylation remains strongly correlated with MDA, CRP and stages of CRF.

conclusionThis study indicates that the DNA hypomethylation of p66shc promoter was correlated with oxidative and inflammatory stress and the disease stages in CRF patients.

Indexed as

Promoter Regions, GeneticAdultAgedAged, 80 and overCase-Control StudiesDNA MethylationFemaleHumansInflammationKidney Function TestsMaleMalondialdehydeMiddle AgedOxidative StressRenal Insufficiency, ChronicSrc Homology 2 Domain-Containing, Transforming Protein 1MalondialdehydeSHC1 protein, humanSrc Homology 2 Domain-Containing, Transforming Protein 1

Identifiers

PMID34529688
PMCPMC8445414
OpenAlexW3199443218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.